SAN DIEGO, California — September 16, 2025 — Leads & Copy — Sigyn Therapeutics, Inc. (OTCQB: SIGY) announced that Chairman and CEO Jim Joyce will present live at the Life Sciences Virtual Investor Forum, hosted by VirtualInvestorConferences.com, on September 18th, 2025, at 3:00 PM ET. Investors are invited to ask questions in real-time during the interactive online event, and an archived webcast will be available afterward. One-on-one meetings are scheduled for September 19th. Registration and a system check are recommended.
Sigyn Therapeutics introduced Sigyn Therapy™ on September 3rd as a device to reduce inflammatory molecules and cholesterol-carrying lipoproteins linked to major adverse cardiovascular events (MACE). Cardiovascular disease is the leading cause of death worldwide.
Sigyn Therapeutics is developing dialysis-like therapies for cardiovascular disease and cancer. Sigyn Therapy™ is a whole blood adsorption technology to treat cardiovascular disease by reducing inflammatory molecules and targeting cholesterol transporting lipoproteins. The company is also developing cancer therapies: ImmunePrep™ to optimize immunotherapeutic antibody delivery; ChemoPrep™ to enhance targeted chemotherapy delivery; and ChemoPure™ to reduce chemotherapy toxicity. The Company plans to advance its cancer treatment candidates through joint venture development relationships.
Jim Joyce, CEO, Inventor, Email: jj@SigynTherapeutics.com
Source: Sigyn Therapeutics
